FDA approves Itovebi for locally advanced, metastatic breast cancer
The U.S. Food and Drug Administration has approved Itovebi (inavolisib), in combination with palbociclib (Ibrance) and ...
Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause
Despite past performance issues, Arvinas has a solid cash runway. Learn more about ARVN stock's potential and why a cautious ...
Medpage Today on MSN6d
PI3K Inhibitor Wins FDA Approval for Advanced Breast Cancer
The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and ...
FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Approval is based on Phase III INAVO120 results, showing the Itovebiâ„¢ (inavolisib)-based regimen more than doubled ...
Medscape6d
FDA Approves Inavolisib for HR+, HER2−, Advanced Breast Cancer With PIK3CA Mutation
The FDA also approved the FoundationOne Liquid CDx assay to identify patients who qualify for the newly approved treatment.
Targeted Oncology6d
FDA Approves Inavolisib Plus Standard Therapy in PIK3CA-Mutant Breast Cancer
The approval of inavolisib is supported by findings from the phase 3 INAVO120 study evaluating the agent plus palbociclib and ...
News Medical on MSN8h
FDA-approved breast cancer drug shows promise for appendix cancer
Researchers at University of California San Diego School of Medicine found an FDA-approved drug used to treat breast cancer has the potential to be an effective therapeutic for a specific type of ...
MedPage Today7d
PI3K Inhibitor Wins FDA Approval for Advanced Breast Cancer
Opens in a new tab or window The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and fulvestrant to treat locally advanced ...
Managed Healthcare Executive5d
FDA Approves Itovebi for Metastatic Breast Cancer
Itovebi is approved to treat patients with PIK3CA-mutated HR-positive, HER2 negative metastatic breast cancer in combination ...
Monthly Prescribing Reference6d
Itovebi Approved for Advanced Breast Cancer With PIK3CA Mutation
Itovebi is supplied as a tablet in 2 dosage strengths: 3mg and 9mg. Patients should be selected for treatment based on the presence of 1 or more PIK3CA mutations in plasma specimens. The FDA has ...